MarkARubinMD

PubMed

• The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer.
  Lucie Van Emmenis, Sheng-Yu Ku, Kaitlyn Gayvert, Jonathan R Branch, Nicholas J Brady, Subhasree Basu, Michael Russell, Joanna Cyrta, Aram Vosoughi, Verena Sailer, Huss...> ;Cancer Research Communications. 2023 Aug 1
• 1 citations
  Author Correction: Analyses of non-coding somatic drivers in 2,658 cancer whole genomes.
  Esther Rheinbay, Morten Muhlig Nielsen, Federico Abascal, Jeremiah A Wala, Ofer Shapira, Grace Tiao, Henrik Hornshøj, Julian M Hess, Randi Istrup Juul, Ziao Lin, Lars ...> ;Nature. 2023 Feb 1
• 23 citations
  An introduction to the WHO 5th edition 2022 classification of testicular tumours.
  Daniel M Berney, Ian Cree, Vishal Rao, Holger Moch, John R Srigley, Toyonori Tsuzuki, Mahul B Amin, Eva M Comperat, Arndt Hartmann, Santosh Menon, George J Netto, Mark...> ;Histopathology. 2022 Oct 1
• 10 citations
  The evolving landscape of prostate cancer somatic mutations.
  Kellie Cotter, Mark A Rubin> ;The Prostate. 2022 Aug 1
• 12 citations
  Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies.
  Joanna Cyrta, Davide Prandi, Arshi Arora, Daniel H Hovelson, Andrea Sboner, Antonio Rodriguez, Tarcisio Fedrizzi, Himisha Beltran, Dan R Robinson, Anuradha Gopalan, La...> ;The Journal of Pathology. 2022 Jul 1
• 6 citations
  Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET-rearranged thyroid cancer.
  Renuka Raman, Jacques A Villefranc, Timothy M Ullmann, Jessica Thiesmeyer, Viviana Anelli, Jun Yao, James R Hurley, Chantal Pauli, Rohan Bareja, Kenneth Wha Eng, Princ...> ;The Journal of Experimental Medicine. 2022 Jun 6
• 40 citations
  WHO 2022 landscape of papillary and chromophobe renal cell carcinoma.
  João Lobo, Riuko Ohashi, Mahul B Amin, Daniel M Berney, Eva M Compérat, Ian A Cree, Anthony J Gill, Arndt Hartmann, Santosh Menon, George J Netto, Maria R Raspollini, ...> ;Histopathology. 2022 Oct 1
• 11 citations
  Alterations in homologous recombination repair genes in prostate cancer brain metastases.
  Antonio Rodriguez-Calero, John Gallon, Dilara Akhoundova, Sina Maletti, Alison Ferguson, Joanna Cyrta, Ursula Amstutz, Andrea Garofoli, Viola Paradiso, Scott A Tomlins...> ;Nature Communications. 2022 May 3
• 5 citations
  Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.
  Jacqueline Fontugne, Peter Y Cai, Hussein Alnajar, Bhavneet Bhinder, Kyung Park, Huihui Ye, Shaham Beg, Verena Sailer, Javed Siddiqui, Mirjam Blattner-Johnson, Jaclyn ...> ;JCI Insight. 2022 Feb 22
• 41 citations
  The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
  Neha Singh, Varune R Ramnarine, Jin H Song, Ritu Pandey, Sathish K R Padi, Mannan Nouri, Virginie Olive, Maxim Kobelev, Koichi Okumura, David McCarthy, Michelle M Hann...> ;Nature Communications. 2021 Dec 21
• 23 citations
  Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression.
  Marco Bolis, Daniela Bossi, Arianna Vallerga, Valentina Ceserani, Manuela Cavalli, Daniela Impellizzieri, Laura Di Rito, Eugenio Zoni, Simone Mosole, Angela Rita Elia,...> ;Nature Communications. 2021 Dec 2
• 11 citations
  Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings.
  Ursula M Vogl, Tomasz M. Beer, Ian D. Davis, Neal D. Shore, Christopher Sweeney, Piet Ost, Gerhardt Attard, Alberto Bossi, Johann S. de Bono, Charles G. Drake, Eleni E...> ;European Journal of Cancer. 2021 Nov 26
• 15 citations
  G3BP1 inhibits Cul3SPOP to amplify AR signaling and promote prostate cancer.
  Chandrani Mukhopadhyay, Chenyi Yang, Limei Xu, Deli Liu, Yu Wang, Dennis Huang, Lesa D. Deonarine, Joanna Cyrta, Elai Davicioni, Andrea Sboner, Brian D. Robinson, Arul...> ;Nature Communications. 2021 Nov 18
• 20 citations
  Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors.
  Matthew J. Mosquera, Sungwoong Kim, Rohan Bareja, Zhou Fang, Shuangyi Cai, Heng Pan, Muhammad Asad, Maria Laura Martin, Michael Sigouros, Florencia M. Rowdo, Sarah Ack...> ;Advanced Materials. 2021 Nov 14
• 5 citations
  A Functional Precision Oncology Approach to Identify Treatment Strategies for Myxofibrosarcoma Patients.
  Chantal Pauli, Lamberto De Boni, Jonathan E Pauwels, Yanjiang Chen, Lara Planas-Paz, Reid Shaw, Brooke M. Emerling, Carla Grandori, Benjamin D. Hopkins, Mark A. Rubin> ;Molecular Cancer Research. 2021 Nov 2
• 9 citations
  PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations
  Alexander von Werdt, Laura P. Brandt, Orlando D. Schärer, Mark A. Rubin> ;JCO Precision Oncology. 2021 Oct 22
• 9 citations
  Comparative pathology of dog and human prostate cancer
  Toby Ryman-Tubb, Jennifer Lothion-Roy, Veronika M. Metzler, Anna E. Harris, Brian D. Robinson, Albert A. Rizvanov, Jennie N. Jeyapalan, Victoria James, Gary C.W. Engla...> ;Veterinary Medicine and Science. 2021 Oct 10
• 27 citations
  Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us.
  Geniver El Tekle, Tiziano Bernasocchi, Arun M. Unni, Francesco Bertoni, Davide Rossi, Mark A. Rubin, Jean-Philippe Theurillat> ;Trends in Cancer. 2021 Sep 1
• 19 citations
  PI5P4Ks drive metabolic homeostasis through peroxisome-mitochondria interplay.
  Archna Ravi, Lavinia Palamiuc, Ryan M. Loughran, Joanna Triscott, Gurpreet K. Arora, Avi Kumar, Vivian Tieu, Chantal Pauli, Matthias Reist, Rachel J. Lew, Shauna L. Ho...> ;Developmental Cell. 2021 Jun 7
• 18 citations
  Mapping of m6A and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-Low Induction of Therapy Resistance.
  Kellie A. Cotter, John Gallon, Nadine Uebersax, Philip Rubin, Kate D. Meyer, Salvatore Piscuoglio, Samie R. Jaffrey, Mark A. Rubin> ;Molecular Cancer Research. 2021 Jun 4
• 28 citations
  Prostate cancer patient-derived organoids: detailed outcome from a prospective cohort of 81 clinical specimens.
  Raphaëlle Servant, Michele Garioni, Tatjana Vlajnic, Melanie Blind, Heike Pueschel, David C Müller, Tobias Zellweger, Arnoud J. Templeton, Andrea Garofoli, Sina Malett...> ;The Journal of Pathology. 2021 Jun 2
• 19 citations
  CD38 in Advanced Prostate Cancers.
  Christina Guo, Mateus Crespo, Bora Gurel, David Dolling, Jan Rekowski, Adam Sharp, Antonella Petremolo, Semini Sumanasuriya, Daniel Nava Rodrigues, Ana Ferreira, Rita ...> ;European Urology. 2021 Jun 1
• 13 citations
  Targeting the epichaperome as an effective precision medicine approach in a novel PML - SYK fusion acute myeloid leukemia
  Mayumi Sugita, David Wilkes, Rohan Bareja, Kenneth Eng, Sarah Nataraj, Reyna A. Jimenez-Flores, LunBiao Yan, Jeanne P. De Leon, Jaclyn A. Croyle, Justin D. Kaner, Swat...> ;NPJ Precision Oncology. 2021 May 26
• 3 citations
  Histological and immunohistochemical investigation of canine prostate carcinoma with identification of common intraductal carcinoma component.
  Simone de Brot, Jennifer Lothion-Roy, Llorenç Grau-Roma, Emily White, Franco Guscetti, Mark A. Rubin, Nigel P. Mongan> ;Veterinary and Comparative Oncology. 2021 May 7
• 7 citations
  Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey
  Samson W. Fine, Kiril Trpkov, Mahul B. Amin, Ferran Algaba, Manju Aron, Dilek Ertoy Baydar, Antonio Beltran, Fadi Brimo, John C. Cheville, Maurizio Colecchia, Eva Comp...> ;Urologic Oncology. 2021 May 1
• Join now to see all

Journal Articles

• Transcriptomic Heterogeneity in Multifocal Prostate Cancer  
  Mark A. Rubin, Aaron M. Udager, Nicole E. Curci, Simpa S. Salami, Scot A. Tomlins, The Journal of Clinical Investigation
• Publisher Correction: Suppression of Insulin Feedback Enhances the Efficacy of PI3K Inhibitors  
  Siddhartha Mukherjee, Marcus D Goncalves, Mark A Rubin, Nature
• Suppression of Insulin Feedback Enhances the Efficacy of PI3K Inhibitors  
  Marcus D Goncalves, Siddhartha Mukherjee, Mark A Rubin, Nature
• A comparative study of ERG status assessment on DNA-, mRNA-, and protein levels using unique samples from a Swedish biopsy cohort  
  Svensson MA, Perner S, Ohlson AL, Day JR, Groskopf J, Kirsten R, Sollie T, Helenius G, Anderseeon SO, Demichelis F, Andren O, Rubin MA, Diagn Mol Pathol, 1/1/2014
• Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing  
  Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J et al, Nat Biotechnol, 10/20/2013
• Frequent truncating mutations of STAG2 in bladder cancer  
  Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahloun AG, Ozawa T, Gerard J, Zhuang D, Zhang S, Navai N, Siefker-Radtke A, Phillips JJ, Robinson BD, Rubin MA,..., Nat Genet, 10/13/2013
• Racial differences in withdrawal of mechanical ventilation do not alter mortality in neurologically injured patients  
  Rubin MA, Dhar R, Diringer MN, J Crit Care, 10/8/2013
• Integrative annotation of variants from 1,092 humans: application to cancer genomics  
  Khurana E, Fu Y, Colonna V, Mu XJ, Kang HM, Lappalainen T, Sboner A, Lochovsky L et al, Science, 10/4/2013
•  
  Barbieri CE, Sboner A, Rubin MA, Garraway LA, J Pathol, 10/1/2013
• The mutational landscape of prostate cancer  
  Barbieri CE, Bangma CH, Bjartell A, Catto JW, Culig Z, Gronberg H, Luo J, Visakorpi T, Rubin MA, Eur Urol, 10/1/2013
• Somatic copy number alterations by whole exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer  
  Menon R, Deng M, Ruenauver K, Queisser A, Offermann A, Boehm D, Vogel W, Scheble V, Fend F, Kristiansen G, Wernert N, Oberbeckmann N, Biskup S, Rubin MA, Shaikhibrahim..., J Pathol, 9/23/2013
• Variants at IRX4 as prostate cancer expression quantitative trait loci  
  Xu X, Hussain WM, Vijai J, Offit K, Rubin MA, Demichelis F, Klein RJ, Eur J Hum Genet, 9/11/2013
• Molecular characterization of prostate cancer following androgen deprivation: The devil in the details  
  Barbieri CE, Rubin MA, Eur Urol, 8/30/2013
• Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma  
  Antonescu CR, Le Loarer F, Mosquera JM, Sboner A, Zhang L, Chen CL, Chen HW, Pathan N, Krausz T, Dickson BC, Weinreb I, Rubin MA, Hameed M, Fletcher CD, Genes Chromosomes Cancer, 8/1/2013
• Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2  
  Mukhopadhyay NK, Kim J, You S, Morello M, Hager MH, Huang WC, Ramachandran A, Yang J, Cinar B, Rubin MA, Adam RM, Oesterreich S, Di Vizio D, Freeman MR, Oncogene, 7/29/2013
• V-ets erythroblastosis virus E26 oncogene homolog (avian)/Trefoil factor 3/high-molecular-weight cytokeratin triple immunostain: a novel tissue-based biomarker in pros...  
  Park K, Chiu YL, Rubin MA, Demichelis F, Mosquera JM, Hum Pathol, 7/12/2013
• Comprehensive molecular characterization of clear cell renal cell carcinoma  
  The Cancer Genome Atlas Research Network; Analysis working group: Baylor College of Medicine, Creighton CJ, Morgan M, Gunaratne PH,…Weill Cornell Medical College, Mosq..., Nature, 7/4/2013
• Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer  
  Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, Bueti G, Siddiqui J, Tomlins SA, Wei JT, Chinnaiyan AM, Rubin MA, Sanda MG, Urol Oncol, 7/1/2013
• Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma  
  Bhalla R, Kunju LP, Tomlins SA, Christopherson K, Cortez C, Carskadon S, Siddiqui J, Park K, Miguel Mosquera J, Pestano GA, Rubin MA, Chinnaiyan AM, Palanisamy N, Mod Pathol, 6/1/2013
• Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer  
  Schaefer G, Mosquera JM, Ramoner R, Park K, Romanel A, Steiner E, Horninger W, Bektic J, Ladurner-Rennau M, Rubin MA, Demichelis F, Klocker H, Prostate Cancer Prostatic Dis, 6/1/2013
• Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma  
  Mosquera JM, Sboner A, Zhang L, Kitabayashi N, Chen CL, Sung YS, Wexler LH, Laquaglia MP, Edelman M, Sreekantaiah C, Rubin MA, Antonescu CR, Genes Chromosomes Cancer, 6/1/2013
• Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity  
  Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, Macdonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus DM, Stephens PJ, Mosquera JM, Cronin MT, Rubin MA, Eur Urol, 5/1/2013
• Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover  
  Geng C, He B, Xu L, Barbieri CE, Eedunuri VK, Chew SA, Zimmermann M, Bond R, Shou J, Li C, Blattner M, Lonard DM, Demichelis F, Coarfa C, Rubin MA, Zhou P, O'Malley BW..., Proc Natl Acad Sci USA, 4/23/2013
• Identifying an ERG-positive subclass with clinical progression using expression profiling  
  Sboner A, Rubin MA, Eur Urol, 3/26/2013
• Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course  
  Perner S, Rupp NJ, Braun M, Rubin MA, Moch H, Dietel M, Wernert N, Jung K, Stephan C, Kristiansen G, Int J Cancer, 2/15/2013
• Join now to see all

Books/Book Chapters

• Textbook of Genitourinary Oncology. 
  Chapter: Prostate cancer: molecular pathology and biologic determinants. 
  Rubin MADr. Nicholas Vogelzang2007

Lectures

• Cancers associated to ETS transcription factor translocations. 
  Italy - 11/1/2013
• Pathways to Therapy. 
  5/1/2013
• Embracing Excellence in Prostate, Bladder and Kidney Cancer. 
  Barcelona, Spain - 11/1/2012
• Strategies to define novel prostate cancer target for therapy. 
  Leuven, Flanders, Belgium - 5/1/2012
• "Distinguished Lecture" Seminar Series. 
  Heidelberg, Germany - 5/1/2012
• Frontiers in Cancer Prevention. 
  10/1/2011
• Diagnosing Significant Prostate Cancer. 
  Switzerland - 6/1/2011
• Systems Biology of Prostate Cancer. 
  Berlin, Germany - 10/1/2010
• EDRN Prostate Cancer Biomarker Program and Testing Opportunities. 
  7/1/2010
• Genetic and Molecular Predictors in Genitourinary Malignancies - Pathway Signatures in Genitourinary Malignancies. 
  6/1/2010
• Next Generation View on the Early Detection of Prostate Cancer. 
  1/1/2010
• Discovery of Recurrent Prostate Cancer Gene Fusions: Biological and Clinical Implications. 
  New York, NY - 6/1/2008
• Prostate Cancer. 
  San Diego, CA - 4/1/2008
• TMPRSS2-ETS Fusion Prostate Cancer Emerging Clinical Implications. 
  Denver, CO - 3/1/2008
• Emerging Technology that are Improving Diagnosis and Therapy. 
  Tucson, AZ - 3/1/2008
• Gene Fusion in Prostate Cancer. 
  Milan, Italy - 3/1/2008
• Pathology and clinical implications of gene fusion prostate cancer. 
  Cambridge, MA - 2/1/2008
• TMPRSS@-ERG Prostate Cancer: The most Common recurrent Gene Fusion and Biologic and Clinical implications. 
  1/1/2008
• Origins of Prostate Cancer: Understanding Molecular Heterogeneity 
  1/1/2008
• Molecular Biomarkers for Solid Tumors. 
  Los, Angeles, CA - 11/1/2007
• Clinical and Biological implications of TMPRSS2-ETS fusion prostate cancer. 
  Barcelona, Spain - 11/1/2007
• Molecular Basis of Prostate Cancer TMPRSS2-ERG Prostate Cancer: New Insights in prostate cancer heterogeneity Scientific Retreat. 
  Lake Tahoe, NV - 10/1/2007
• TMPRSS-ETS in Prostate Cancer: An update on clinical and pathologic Implications. 
  10/1/2007
• Current trends in GU Malignancies. 
  New York, NY - 10/1/2007
• Interfacing Animal Models with Human Cancer Biomarker Development. 
  Rockville, MD - 7/1/2007
• Join now to see all